Newsroom | 18577 results

CAMBRIDGE, England--(BUSINESS WIRE)--Enhanced Genomics (‘Enhanced’ or ‘the Company’), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced Katerina Leftheris, Ph.D. has joined its Board of Directors. Katerina’s appointment as a Director forms part of the Company’s ongoing strategy to expand its internal therapeutics pipeline for drug targets identified using its 3D multi-omics platform. K...

DURHAM, N.C.--(BUSINESS WIRE)--Naveris, Inc., the leader in precision oncology diagnostics for viral-driven cancers, today announced that it will be highlighting new data supporting the use of blood-based ctDNA tests to improve post-treatment surveillance protocols in both head-and-neck and anal cancers at the 44th Annual J.P. Morgan Healthcare Conference, to be held January 12-15, 2026, in San Francisco, CA. Recent data published in Cancers reinforces the value of the Naveris Tumor Tissue Modi...

BRISBANE, Calif.--(BUSINESS WIRE)--Corporate presentation at 7:30 AM PST on January 15 in room Elizabethan A at the Westin St. Frances hotel, San Francisco...

BOSTON--(BUSINESS WIRE)--Aurora Therapeutics today announced its official launch to transform personalized gene editing from a one-patient breakthrough into a scalable model capable of bringing therapies to millions of patients with rare diseases. The company launches with a $16 million seed financing from Menlo Ventures to create the first platform for treating rare genetic mutations that have historically been impossible to address at scale. Aurora was founded by Jennifer Doudna, Ph.D., CRISP...

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that Joseph Payne, President & Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, on Monday, January 12, 2026, at 5:15 p.m. Pacific Time. About Arcturus Found...

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the “Board”) has appointed Everett Cunningham as the Company’s next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Execu...

MENLO PARK, Calif.--(BUSINESS WIRE)--Octave Bioscience, Inc., a commercial stage precision medicine company pioneering biomarker driven solutions for multiple sclerosis, Parkinson’s disease and other neurodegenerative diseases today announced the appointment of Kirk Stockwood as Senior Vice President, Commercial. Mr. Stockwood will spearhead Octave’s commercial strategy as the company scales operations and expands the reach of its precision neurology platform. Mr. Stockwood brings over 20 years...

DUBLIN--(BUSINESS WIRE)--The "Extracellular Vesicle Cargo and Functional Analysis Tools 2026 (Portland, Oregon, United States - March 15-16, 2026)" conference has been added to ResearchAndMarkets.com's offering. The host is honored to welcome Professor Terry Morgan, Professor of Pathology and Laboratory Medicine, Oregon Health and Science University and Professor Daniel Chiu, A. Bruce Montgomery Professor of Chemistry, University of Washington as the Co-Chairpersons of the Conference. This conf...

ÉDIMBOURG, Écosse--(BUSINESS WIRE)--RoslinCT, une organisation mondiale de développement et de fabrication sous contrat (CDMO) spécialisée dans les thérapies cellulaires avancées, et BOOST Pharma, une biotech de phase clinique développant des thérapies cellulaires pionnières pour les maladies squelettiques pédiatriques rares, annoncent aujourd’hui un partenariat de fabrication stratégique pour soutenir le développement de la thérapie cellulaire de BOOST Pharma, BT-101, pour le traitement des no...

EDIMBURGO, Escocia--(BUSINESS WIRE)--RoslinCT, una organización internacional dedicada al desarrollo y la fabricación por contrato (CDMO) especializada en terapias celulares avanzadas, y BOOST Pharma, una empresa biotecnológica en fase clínica que desarrolla terapias celulares pioneras para enfermedades óseas pediátricas raras, han anunciado hoy un acuerdo estratégico de fabricación para impulsar el desarrollo de la terapia celular BT-101 de BOOST Pharma, destinada al tratamiento de bebés con o...